Venn Therapeutics is an immuno-oncology company developing drugs that transform tumor-resident innate immune cells to an anti-tumor phenotype reversing the immunosuppressive microenvironment found within tumors. This approach can expand the number of patients who can be effectively treated with immuno-oncology modalities.
In May 2017, The University of Utah Research Foundation partnered with Venn Therapeutics, to advance its novel small molecule ?-catenin/BCL9 inhibitor, invented by Dr. Haitao (Mark) Ji.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/venn-therapeutics” connections=”true” suffix=””]
Venn Therapeutics is pursuing novel therapies using STING (Stimulator of Interferon Genes) agonists and potentially disruptive Oncolytic Virus therapies using Bovine Herpes Virus. Venn assets includes: 1. STING agonist. Novel innate immune pathway.
2. Novel small molecule ?-catenin/BCL9 inhibitor 3. Oncolytic Virus. Bovine virus, potentially disruptive.
In Apr 2018, Venn Therapeutics, acquired an exclusive rights from the University of California, San Francisco (UCSF) to further advance its novel integrin ?v?8 antibody, created by Dr. Stephen Nishimura Group at UCSF. Integrin ?v?8 is expressed by a wide variety of tumor cells and its expression correlates with solid tumor progression. The inhibition of integrin ?v?8 prevents activation of latent TGF-?.
Venn Therapeutics was awarded funding from the University of South Florida Research Foundations Seed Capital Accelerator program.